Plaque-type Psoriasis
Conditions
Keywords
psoriasis
Brief summary
The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin.
Interventions
DRUGAN2728 Ointment
5mg/cm2, BID
DRUGAN2728 Vehicle
5mg/cm2 BID
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* White males, 18 - 55 years (inclusive) of age at the time of randomization. * Body weight between 60-90 kg (Body Mass Index \[BMI\] between 19 and 30 kg/m2 \[inclusive\]). * Willing and able to comply with study instructions and commit to all follow-up visits. * Have adequate venous access to permit repeated PK sampling. * Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol-related procedures. * Non-smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication). For psoriasis patients (in addition to the above criteria): * Clinical diagnosis of stable plaque-type psoriasis with active plaques involving 5%-20% of total BSA excluding face, scalp and groin.
Exclusion criteria
* History of serious adverse reactions or hypersensitivity to any drug; or known allergy to any of the test product(s) or any components in the test product(s) or history of hypersensitivity; or allergic reactions to any of the study preparations as described in the Investigator's Brochure. * Any clinically significant central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the Investigator may place the subject at an unacceptable risk as a participant in this trial or may interfere with the distribution, metabolism or excretion of drugs. * Abnormal physical findings of clinical significance at the Screening examination or Baseline which would interfere with the objectives of the study. * History of orthostatic hypotension (an increase in HR ≥20 bpm accompanied by a ≥20 mm Hg drop in SBP and/or ≥10 mm Hg drop in DBP) present at Screening. * Clinically significant abnormal laboratory values (as determined by the Investigator) at the Screening evaluation. * Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis). * 12-lead ECG obtained at Screening with: PR \>240 msec, QRS \>110 msec and QTc \>450 msec, bradycardia (\<50 bpm) or clinically significant minor ST wave changes on the Screening ECG, or any other changes on the Screening ECG that would interfere with measurement of the QT interval. * Major surgical interventions within 6 months of the study. * Has a positive pre-study Hepatitis B surface antigen; positive Hepatitis C (HCV) antibody or detectable HCV ribonucleic acid (RNA); or positive HIV antibody result. * Use of prescription or non-prescription drugs, including vitamin supplements, herbal and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, or use of St. John's Wort within 28 days prior to the first dose of study medication. However, the Investigator and study team can review medication use on a case by case basis to determine if its use would compromise subject safety or interfere with study procedures or data interpretation. By exception, the subject may take paracetamol or acetaminophen (≤2 g/day) or ibuprofen (≤1600 mg/day) up to 48 h prior to the first dose of study medication. * Has a history of regular alcohol consumption averaging \>14 drinks/week (1 drink \[100 mL wine or 280 mL standard strength beer or 30 mL of 80 proof distilled spirits\]) within 6 months of the Screening visit. * Loss of 500 mL blood or more during the 3 month period before the study, e.g., blood donor. * People that follow vegetarian or vegan diets. * Symptoms of a significant somatic or mental illness in the four week period preceding drug administration. * History of drug abuse or dependence within 12 months of the study. * Positive pre-study urine drug and alcohol screen. A minimum list of drugs that will be screened for include benzodiazepines, opiates, methadone metabolite (EDDP), sympathomimetic amines, cannabinoids, barbiturates, cocaine, and ethanol. (Suspected false positive results may be repeated at the discretion of the Investigator.) * Concurrent or recent (within 60 days) participation in another drug or device research study. * Considered by the Investigator to be unsuitable candidate for this study. Use of AN2728 in a previous clinical trial. For psoriasis patients (in addition to the above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | Up to 21 days | 12-lead ECG, clinical laboratory tests, urinalysis, spontaneous/elicited adverse event (AE) reporting, local site reactions, physical exam and vital signs (blood pressure, heart rate). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic profile | 16 Days Maximum | Non-compartmental analysis of classic PK parameters: AUC(0-t), Cmax, Tmax, terminal t-1/2 (computed if data from majority of subjects permit) of AN2728, on Days 1 and 7 (or last day of administration). Trough plasma concentrations at the end of the dosing interval (Ctrough) collected at pre-morning dose. |
Countries
Australia
Outcome results
None listed